Informationen:
Fehler:
ID
14817
Beschreibung
A Clinical Trial to Study the Effects of Nanoparticle Based Paclitaxel Drug, Which Does Not Contain the Solvent Cremophor, in Advanced Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00915369
Link
https://clinicaltrials.gov/show/NCT00915369
Stichworte
Versionen (1)
- 29.04.16 29.04.16 -
Hochgeladen am
29. April 2016
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
Eligibility Advanced Breast Cancer NCT00915369
Eligibility Advanced Breast Cancer NCT00915369
- StudyEvent: Eligibility
Ähnliche Modelle
Eligibility Advanced Breast Cancer NCT00915369
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
advanced breast cancer
Item
female patients with histopathologically /cytologically confirmed advanced breast cancer, refractory / recurrent* to previous anthracycline treatment as adjuvant or first line therapy for metastasis.
boolean
C3495917 (UMLS CUI [1,1])
C0205269 (UMLS CUI [1,2])
C0205269 (UMLS CUI [1,2])
receptor status unknown
Item
patients with er/pr -ve or er/pr receptor status unknown (defined as no histopathological evidence for confirmation of er/pr status)
boolean
C0279758 (UMLS CUI [1])
age
Item
patients must be of 18-65 years of age (inclusive of both)
boolean
C0001779 (UMLS CUI [1])
ecog
Item
patients with ecog performance status between 0 - 2
boolean
C1520224 (UMLS CUI [1])
measurable lesion
Item
patients with at least one measurable lesion as per recist
boolean
C1513041 (UMLS CUI [1])
er/pr positive status
Item
patients with er/pr positive status. patients who demonstrate her2 over expression will be excluded. alternatively, the patients enrolled should have previously received trastuzumab. her2 over expression should be demonstrated by ihc 3+, ihc 2+
boolean
C1719706 (UMLS CUI [1])
C0069515 (UMLS CUI [2])
C0069515 (UMLS CUI [2])
her2+ detected with fish/cis
Item
her2+ detected with fish/cis
boolean
C2316574 (UMLS CUI [1])
hypersensitivity to paclitaxel or any other taxane
Item
patients with known history of hypersensitivity to paclitaxel or any other taxane or compounds chemically / biologically related to paclitaxel or excipients.
boolean
C0020517 (UMLS CUI [1,1])
C0215136 (UMLS CUI [1,2])
C0215136 (UMLS CUI [1,2])
chemotherapy, hormonal therapy immunotherapy, therapy with biologicals or radiotherapy
Item
patients requiring any concurrent chemotherapy, hormonal therapy immunotherapy, therapy with biologicals or radiotherapy for the disease. (patients requiring local radiotherapy for non- target bone lesion will be included).
boolean
C0392920 (UMLS CUI [1])
C0021083 (UMLS CUI [2])
C0021083 (UMLS CUI [2])
cns lesions
Item
patients with known cns lesions (brain metastasis or carcinomatous meningitis).
boolean
C0742468 (UMLS CUI [1])